Adverum Biotechnologies, Inc. - Common Stock (NQ:ADVM)

4.360 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Adverum Biotechnologies, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in...

Via MarketMinute

Halper Sadeh LLC Encourages CMA, ADVM, HOUS Shareholders to Contact the Firm to Discuss Their Rights

November 18, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

This Yum! Brands Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

November 17, 2025

Via Benzinga

Eli Lilly To Acquire Adverum Biotechnologies ↗

October 24, 2025

Via Stocktwits

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

November 17, 2025

Via Benzinga

This Dell Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

November 17, 2025

Via Benzinga

ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders

October 27, 2025

From Halper Sadeh LLC

Via Business Wire

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

October 25, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Halper Sadeh LLC Encourages ADVM, MOFG, HSII Shareholders to Contact the Firm to Discuss Their Rights

October 24, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections ↗

October 24, 2025

Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones.

Via Benzinga

ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. is Fair to Shareholders

October 24, 2025

From Halper Sadeh LLC

Via GlobeNewswire

In today's session, these stocks are experiencing unusual volume. ↗

September 24, 2025

In today's session, these stocks are experiencing unusual volume.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 22, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

May 09, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

May 05, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

April 29, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

April 25, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

April 21, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

April 17, 2025

From Pomerantz LLP

Via GlobeNewswire

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

April 17, 2025

Via Benzinga

ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm

April 13, 2025

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

April 12, 2025

From Pomerantz LLP

Via GlobeNewswire

Top movers in Wednesday's pre-market session ↗

April 09, 2025

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 31, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 05, 2024

Via Benzinga

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q2 2024 ↗

August 12, 2024

ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Around $88M Bet On NextDecade? Check Out These 3 Stocks Insiders Are Buying ↗

August 01, 2024

Via Benzinga

More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying ↗

July 19, 2024

Via Benzinga

Adverum Releases Interim Data From Gene Therapy Study For Blindness Disorder, Prepares For Pivotal Study ↗

July 17, 2024

Adverum Biotechnologies presented 26-week interim data from the LUNA Phase 2 trial for Ixo-vec in wet AMD. The analysis showed significant reductions in anti-VEGF injections and positive visual...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.